- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00349193
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
April 7, 2011 updated by: Teva Branded Pharmaceutical Products R&D, Inc.
A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects
Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute brain lesions.
The duration of the current study is 36 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
306
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to give written informed consent
- Confirmed MS diagnosis as defined by the McDonald criteria
- R-R MS disease course.
- At least one gadolinium-enhanced lesion on screening MRI
- Women of child-bearing potential must practice a reliable method of birth control.
- Must understand the requirements of the study and agree to comply with the study protocol.
Exclusion Criteria:
- Subjects who suffer from any form of progressive MS.
- Any condition which the investigator feels may interfere with participation in the study.
- Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation,
- Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening
- Previous treatment with immunomodulators within two months prior to screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Laquinimod 0.3 mg
|
laquinimod 0.3mg
|
Active Comparator: Laquinimod 0.6 mg
|
laquinimod 0.6mg
|
Placebo Comparator: Placebo
Blinded Placebo
|
Blinded Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction of brain lesions in the last 4 months of the study
Time Frame: 36 weeks
|
36 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relapse rate
Time Frame: 36 weeks
|
36 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Prof. Giancarlo Comi, Teva Pharmaceutical Industries, Ltd.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2005
Primary Completion (Actual)
June 1, 2006
Study Completion (Actual)
August 1, 2006
Study Registration Dates
First Submitted
June 26, 2006
First Submitted That Met QC Criteria
July 5, 2006
First Posted (Estimate)
July 6, 2006
Study Record Updates
Last Update Posted (Estimate)
April 8, 2011
Last Update Submitted That Met QC Criteria
April 7, 2011
Last Verified
April 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LAQ/5062
- 2004-003943-28 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing Remitting Multiple Sclerosis
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
Clinical Trials on laquinimod 0.3
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedRelapsing Multiple SclerosisUnited States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Moldova, Republic of, Montenegro, North Macedonia and more
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedHuntington's DiseaseUnited States, Canada, Czechia, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedCrohn's DiseaseBelgium, France, Israel, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedA Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus ArthritisLupus ArthritisUnited States, Canada
-
Teva Pharmaceutical Industries, Ltd.TerminatedRelapsing Remitting Multiple SclerosisCzechia, Germany, Hungary, Israel, Italy, Poland, Russian Federation, Spain, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Latvia
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedRelapsing Multiple SclerosisUnited States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedPrimary Progressive Multiple SclerosisUnited States, Canada, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedPharmacokinetics | PharmacodynamicsGermany